Diagnostic utility of GATA3 immunohistochemical expression in urothelial carcinoma

Agarwal, Harshit; Babu, Suresh; Rana, Chanchal; Kumar, Madhu; Singhai, Atin; Shankhwar, Satya Narain; Singh, Vishwajeet; Sinha, Rahul Janak

doi:10.4103/ijpm.ijpm_228_18

Cited by 26 publications

(24 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GATA3 is an established marker of luminal papillary bladder tumours which are the least aggressive tumours and still retain some of the features of the urothelial differentiation (98). Similar to the results of this meta-analysis, four studies reported significant association between GATA3 expression and low grade (51,59,71,86) and low stage (51,59,71,86) tumours. GATA3 expression showed a significant association with tumour histology, with higher expression in UC as opposed to VH and UCDD, both in individual studies (57,60,70,77,79,84,86,90) and in our meta-analysis.…”

Section: Diagnostic Valuesupporting

confidence: 80%

Association Between Estrogen Receptors and GATA3 in Bladder Cancer: A Systematic Review and Meta-Analysis of Their Clinicopathological Significance

et al. 2021

View full text Add to dashboard Cite

BackgroundEstrogen receptors alpha (ERα) and beta (ERβ) and the cooperating protein GATA-binding factor 3 (GATA3) have been implicated in bladder carcinogenesis and tumour progression. GATA3 and ER have been functionally linked in the establishment of luminal fate in breast tissue, but to date their relationship in bladder cancer has not been established. This information will be useful to advance diagnostic and prognostic markers.AimTo determine the relationship between the expression of ERα, ERβ and GATA3 in bladder cancer, disclose their prognostic and diagnostic value and their association with clinicopathological characteristics.MethodsA comprehensive literature search in PubMed database was performed for all immunohistochemical studies of ERα, ERβ and/or GATA3 in bladder cancer patients. We selected eligible studies in accordance with the PRISMA guidelines and evaluated methodological quality and risk of bias based on quality criteria from the reporting recommendations for tumour MARKer (REMARK) prognostic studies. Risk of bias assessment was performed using Review Manager 5. R software was used for all statistical analysis, the packages used were meta and dmetar for the standard meta-analysis, and netmeta for the network meta-analysis.ResultsThirteen studies were eligible for ERα, 5 for ERβ and 58 for GATA3 meta-analysis. Low grade tumours showed significantly lower ERα expression. GATA3 was widely expressed in bladder tumours, especially urothelial carcinomas, with higher expression of GATA3 in low grade and low stage tumours. Data was insufficient to determine the prognostic value of either ERα or ERβ, but GATA3-positivity was associated with higher recurrence free survival. A negative correlation between ERα or ERβ positivity and GATA3 expression was disclosed. Additionally, several sources of heterogeneity were identified, which can be used to improve future studies.ConclusionThe clinicopathological value of ERα and ERβ was inconclusive due to low availability of studies using validated antibodies. Still, this meta-analysis supports GATA3 as good prognostic marker. On the contrary, ERα-positivity was associated to higher grade tumours; while ERα and ERβ were inversely correlated with GATA3 expression. Considering that it has previously been shown that bladder cancer cell lines have functional ERs, this suggests that ERα could be activated in less differentiated cells and independently of GATA3. Therefore, a comprehensive analysis of ERα and ERβ expression in BlaCa supported by complete patient clinical history is required for the identification of BlaCa subtypes and subgroups of patients expressing ERα, to investigate if they could benefit from treatment with hormonal therapy.Systematic Review RegistrationProspero, CRD42021226836.

show abstract

Section: Diagnostic Valuesupporting

confidence: 80%

Association Between Estrogen Receptors and GATA3 in Bladder Cancer: A Systematic Review and Meta-Analysis of Their Clinicopathological Significance

et al. 2021

View full text Add to dashboard Cite

show abstract

“…GATA3 is a dual-zinc finger transcription factor that regulates gene expression in many developing tissues, which is positive in 76% of urothelial carcinomas [17]. It can be effectively used to diagnose urothelial carcinoma, but it has also been reported to be positive in other tumors, including breast cancer.…”

Section: Discussionmentioning

confidence: 99%

“…It can be effectively used to diagnose urothelial carcinoma, but it has also been reported to be positive in other tumors, including breast cancer. This marker can also be effectively used in predicting the probable grade and invasion in biopsy material with poor morphological characteristics [17].…”

Section: Discussionmentioning

confidence: 99%

A Rare Urothelial Malignant Transformation in a Mature Cystic Teratoma of the Ovary

Iijima¹,

Kisu²,

Shiraishi³

et al. 2021

Cureus

View full text Add to dashboard Cite

Approximately 0.17-2% of mature cystic teratomas undergo malignant transformation, of which squamous cell carcinoma (SCC) is the most common, accounting for 80% of these cases. Urothelial malignant transformation is extremely rare. The present study involves a 58-year-old patient who visited the hospital with discomfort in the lower abdomen. USG and pelvic MRI showed a left ovarian mature cystic teratoma. Left salpingo-oophorectomy was performed, and pathological examination revealed urothelial carcinoma transformation of the mature cystic teratoma morphologically and immunohistochemically. No metastasis to other organs was identified by CT after the surgery. Additional surgery, including total hysterectomy, right salpingo-oophorectomy, omentectomy, and dissection of pelvic and para-aortic lymph nodes, was performed without complications. No tumors were identified elsewhere, and the patient's stage was confirmed as IA. She had an uneventful postoperative course and was discharged 10 days later. CT showed no metastasis or recurrence six months later.

show abstract

“…In the present meta-analysis, studies evaluating e valuating Annexin1 expression in canine bladder tumors were not founded. GATA3 is widely used in human medicine as a diagnostic marker (Inoue et al, 2017, Agarwal et al 2019). Interestingly, besides a diagnostic marker, GATA3 has been shown as an important prognostic marker in human bladder cancer (Inoue et al, 2017).…”

Section: Discussionmentioning

confidence: 99%

A comparative meta and in silico analysis of differentially expressed genes and proteins in canine and human bladder cancer

Gambim

Amorim

Alves

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

Diagnostic utility of GATA3 immunohistochemical expression in urothelial carcinoma

Cited by 26 publications

References 2 publications

Association Between Estrogen Receptors and GATA3 in Bladder Cancer: A Systematic Review and Meta-Analysis of Their Clinicopathological Significance

Association Between Estrogen Receptors and GATA3 in Bladder Cancer: A Systematic Review and Meta-Analysis of Their Clinicopathological Significance

A Rare Urothelial Malignant Transformation in a Mature Cystic Teratoma of the Ovary

A comparative meta and in silico analysis of differentially expressed genes and proteins in canine and human bladder cancer

Contact Info

Product

Resources

About